These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 21924904

  • 21. Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study.
    Rhee Y, Song K, Park S, Park HS, Lim SK, Park BW.
    Endocr J; 2013; 60(2):167-72. PubMed ID: 23064476
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.
    Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, Jin L, Warsi G, Argonza-Aviles E, Hohneker J, Ericson SG, Perez EA.
    Cancer; 2012 Mar 01; 118(5):1192-201. PubMed ID: 21987386
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The effect of aromatase inhibitors on bone metabolism.
    Folkestad L, Bjarnason NH, Bjerregaard JK, Brixen K.
    Basic Clin Pharmacol Toxicol; 2009 Jan 01; 104(1):3-10. PubMed ID: 19152547
    [Abstract] [Full Text] [Related]

  • 27. Markers of bone metabolism in women receiving aromatase inhibitors for early-stage breast cancer.
    Barginear M, Clotfelter A, Poznak CV.
    Clin Breast Cancer; 2009 May 01; 9(2):72-6. PubMed ID: 19433386
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
    Hadji P, Bundred N.
    Semin Oncol; 2007 Dec 01; 34(6 Suppl 4):S4-10. PubMed ID: 18068489
    [Abstract] [Full Text] [Related]

  • 30. Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.
    Kamdem LK, Xi J, Clark BL, Gregory BJ, Kidwell KM, Storniolo AM, Stearns V, Hayes DF, Gersch CL, Rae JM, Henry NL, Hertz DL.
    Breast Cancer Res Treat; 2019 Jun 01; 175(2):297-303. PubMed ID: 30747308
    [Abstract] [Full Text] [Related]

  • 31. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
    Nakatsukasa K, Koyama H, Ouchi Y, Ono H, Sakaguchi K, Matsuda T, Kato M, Ishikawa T, Yamada K, Yoshimura M, Koizumi K, Sakurai T, Shigematsu H, Takahashi S, Taira S, Suzuki M, Narui K, Niikura N, Hasegawa Y, Miura D, Konishi E, Taguchi T, Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society.
    Breast Cancer; 2019 Jan 01; 26(1):106-112. PubMed ID: 30054855
    [Abstract] [Full Text] [Related]

  • 32. Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?
    Muslimani AA, Spiro TP, Chaudhry AA, Taylor HC, Jaiyesimi I, Daw HA.
    Clin Breast Cancer; 2009 Feb 01; 9(1):34-8. PubMed ID: 19299238
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Effects of third-generation aromatase inhibitors on bone.
    McCloskey E.
    Eur J Cancer; 2006 May 01; 42(8):1044-51. PubMed ID: 16554149
    [Abstract] [Full Text] [Related]

  • 35. Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer.
    Sergi G, Pintore G, Falci C, Veronese N, Berton L, Perissinotto E, Basso U, Brunello A, Monfardini S, Manzato E, Coin A.
    J Bone Miner Metab; 2012 Jul 01; 30(4):461-7. PubMed ID: 22160398
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Reducing the risk of bone loss associated with breast cancer treatment.
    Hadji P.
    Breast; 2007 Dec 01; 16 Suppl 3():S10-5. PubMed ID: 18023583
    [Abstract] [Full Text] [Related]

  • 38. Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.
    Nakatsukasa K, Koyama H, Ouchi Y, Sakaguchi K, Fujita Y, Matsuda T, Kato M, Konishi E, Taguchi T.
    J Bone Miner Metab; 2019 Sep 01; 37(5):864-870. PubMed ID: 30868270
    [Abstract] [Full Text] [Related]

  • 39. Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.
    Ingle JN.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 2):900s-5s. PubMed ID: 15701884
    [Abstract] [Full Text] [Related]

  • 40. Prevention of osteoporosis after breast cancer.
    Reid DM.
    Maturitas; 2009 Sep 20; 64(1):4-8. PubMed ID: 19709826
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.